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SUMMARY
Studies carried out on individuals being treated long
term with bisphosphonates have provoked considerable interest
and perplexity about the effect that these drugs have on bone
turnover in the long run. 
In fact the experiences reported by numerous researchers
tend to highlight how treatment with high doses of bisphospho-
nates over many years, of individuals with osteoporosis com-
plicated by or secondary to neoplastic pathologies, causes a
suppression of bone turnover that over time predisposes the
bone to the accumulation of micro damage that can then result
in complicated fractures, as in the case described here.
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RIASSUNTO
Studi condotti su soggetti in trattamento a lungo termine
con bifosfonati, hanno scatenato notevole interesse e perples-
sità sull’azione che questi farmaci a lungo andare esplicano
sul turnover osseo.
Infatti le esperienze segnalate da più studiosi tendono ad
e v i d e n z i a re come le terapie con bifosfonati ad alti dosaggi e
protratte per diversi anni, in soggetti con osteoporosi compli-
cate o secondarie a patologie neoplastiche, determinino una
s o p p ressione del turnover osseo, predisponendo l’osso stesso
nel tempo, ad accumulare eventuali microdanni che possono
poi scaturire in fratture complicate, come nel caso qui di segui-
to descritto.
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[Fratture di femore in pazienti in trattamento a lungo termime con bifosfonati: implicazioni per il management]
Recent reports of femoral shaft fractures in
patients being treated long-term with bisphosphona-
tes (BPs), whose biopsies showed evidence of seve-
rely suppressed bone turnover, raised important
concerns about the safety of this class of drugs.
Patients with malignant skeletal conditions, such as
multiple myeloma are potentially at high risk of
s u fering from this complication, considering the
duration of the treatment and the doses of BPs that
these patients are subjected to. In this report we
describe the case of a 56 year-old woman who was
referred for evaluation to the Bone Clinic of
Washington University because of a recent left
femoral shaft fracture.
Her history revealed that she had had a stem
cell transplant in November. 1999 for multiple
myeloma. After the transplant, she was put on a
high dose of steroids and pamidronate infusions at
30 mg monthly for 2 years followed by zoledronate
infusions at 4 mg monthly for 4 years. This was
discontinued when high levels of serum creatinine
were detected and because of concerns about osteo-
necro is of the jaw. One and a half years later, she
developed a left femoral shaft fracture (Figure 1A)
while trying to get up from a squatting position. 
Fig. 1A: left femoral shaft
f r a c t u r e .
She underwent an intramedullary fixation of
the left femur but the insertion of the rod resulted in
the “splitting” of the fractured bone (Figure 1B).   
Follow-up x-rays showed poor healing and
non-union of the fractured bones even 6 months
after surgery.
The levels of serum calcium, alkaline pho-
sphatase, 25-hydroxyvitamin D, parathormone
(PTH) and thyroid stimulating hormone were nor-
mal., but the level of serum creatinine was elevated
at 1.9 ng/ml. Bone mineral density was normal in
the femur and mildly low in the lumbar spine. An
attempt to do a bone biopsy was unsuccessful
because the biopsy needle was unable to penetrate
the “rock-hard” iliac crest. 
BPs play an important role in preventing and
reducing the risk of spinal and non-spinal fractures.
H o w e v e r, numerous studies seem to support the
theory that prolonged exposure to this type of drug
may, over time, lead to the suppression of bone tur-
nover and an accumulation of micro-damage which
can eventually cause fractures. Normally, the posi-
tion of the bones in which these occur are not the
normal ones, like for example the femoral metapha-
ses that are mostly made up of cortical bone.
This data has been confirmed by biochemical
studies on bioptic sections taken from the bones of
individuals who have been on BPs for years, and it
can be seen how the bone turnover is completely
suppressed after six years of treatment; this picture
seems to be the same both for those who use BPs
intravenously and for those who take BPs by
mouth.
The above case illustrates a potential problem
in the management of patients with skeletal fragility
fractures from the prolonged use of BPs. Bone X-
rays from these patients may appear normal, our
p a t i e n t ’s x-rays demonstrate, but in reality these
bones bio-mechanically compromised.
Our patient had a non traumatic fracture of the
left femur, which was complicated by the complete
shattering of the fractured bones during surg i c a l
repair. In fact, the bones of our patient were hard on
the outside, and could not be penetrated by the
needle used for the bone biopsy, but on the inside
the structure of the bone was more “brittle”, and
therefore did not allow optimal fusion after the ope-
ration.
This suggests the likelihood of a hyper-mine-
ralized bone matrix superimposed on an inactive
bone turnover as a possible aetiology of this com-
plication. Recognized trials of IVtherapy with BPs
do not exist.
The treatment, carried out on an outpatient
basis, has a strong impact on the suppression of
bone turnover, and resembles osteoporosis in the
way that it increases fragility inside the bone itself.            
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Fig. 1B: Splitting of the fractured
bone after the intramedullary fixa-
tion of the left femur.
